![]() |
市場調查報告書
商品編碼
1305941
抗凝劑市場 - 按藥物類別(Xa因子抑製劑、肝素)、給藥途徑(口服、注射)、應用(血栓栓塞症、心房顫動、冠狀動脈疾病)、配銷通路和全球預測,2023 - 2032年Anticoagulants Market - By Drug Class (Factor Xa Inhibitors, Heparin), Route of Administration (Oral, Injectables), Application (Thromboembolism, Atrial Fibrillation, Coronary Artery Disease), Distribution Channel & Global Forecast, 2023 - 2032 |
到2032年,全球抗凝劑市場規模將顯著擴大。早期疾病診斷意識的提高為市場成長鋪平了道路。由於對疾病診斷的認知不斷提高,全球各國政府都在投資篩查項目和常規健康檢查,以識別有血栓和相關疾病風險的人群。此外,產品製造商正致力於開發具有先進功能和最大療效的抗凝劑,以鞏固其市場地位。這些因素將共同推動抗凝劑在未來幾年的銷售。
整個抗凝劑市場根據藥物類別、給藥途徑、應用、銷售管道和地區進行分類。
根據藥物類別,肝素細分市場的行業佔有率將在2023年至2032年期間以豐厚的年複合成長率成長。深靜脈血栓、急性冠狀動脈症候群、心房顫動、肺栓塞和其他導致血凝塊形成的疾病的發病率不斷上升,增加了對肝素的需求。據美國肺臟協會統計,僅在美國每年就有約90萬人診斷出肺栓塞。
根據應用,到2032年,心房顫動/撲動領域的抗凝劑市場價值將獲得可觀的成長。心房顫動發生率的成長增加了對抗凝劑的需求。根據美國疾病預防控制中心(CDC)的資料,美國每年有超過454,000例以心房顫動為主要診斷的患者入院治療。此外,監管機構對治療心房顫動的產品批准數量激增也進一步促進了該細分市場的成長。
就配銷通路而言,2022年醫院藥房佔據了抗凝劑市場53.5%的佔有率。以優惠價格購買藥品的便利性增加了患者前往醫院藥房的次數。此外,全球各地政府對醫院基礎設施的投資不斷成長,進一步增加了醫院藥房的數量。這些設施提供以患者為中心的護理,並配備了最先進的醫療設備。
從區域角度來看,歐洲抗凝劑市場規模到2032年將達到140億美元。老年人口的成長及其對慢性疾病的易感性增強了該地區對抗凝劑的需求。心臟病發作、中風等心臟疾病的高發病率進一步提高了產品在歐洲的採用率。該地區也是Boehringer Ingelheim, Bayer AG等行業巨頭的發源地,這些巨頭強調產品創新以在競爭中脫穎而出,這將支持該地區的擴張。
Global Anticoagulants Market size will expand significantly through 2032. Rising awareness about early disease diagnosis is paving the path for market growth. Owing to growing awareness about disease diagnosis, governments across the globe are investing in screening programs and routine health check-ups to identify individuals at risk of developing blood clots and related disorders. Besides, product manufacturers are focusing on developing anticoagulants with advanced capabilities and maximum efficacy to strengthen their market position. These factors, in tandem, will propel anticoagulant sales over the coming years.
The overall anticoagulants market is classified based on drug category, route of administration, application, distribution channel, and region.
Based on the drug category, industry share from the heparin segment will grow at a lucrative CAGR from 2023 to 2032. Increasing prevalence of deep vein thrombosis, acute coronary syndrome, atrial fibrillation, pulmonary embolism, and other disorders that lead to blood clot formation has increased the need for heparin. As per the American Lung Association, pulmonary embolism is diagnosed in around 900,000 people every year in the U.S. alone.
Based on application, the anticoagulants market value from the atrial fibrillation/Flutter segment will register considerable gains through 2032. Growing occurrence of atrial fibrillation has increased the need for anticoagulants. As per CDC, over 454,000 hospital admissions with atrial fibrillation as the primary diagnosis take place every year in the U.S. Moreover, surging product approvals by regulatory bodies for the treatment of this disease are further working in favor of segment growth.
In terms of distribution channel, the hospital pharmacy segment amassed over 53.5% of the anticoagulants market share in 2022. The ease of availability of medicines at discounted prices has increased patient visits to hospital pharmacies. Moreover, growing investment by governments across the globe in hospital infrastructure has further increased the number of hospital pharmacies. These facilities offer patient-centered care and are equipped with cutting-edge medical equipment.
From the regional perspective, Europe anticoagulants market size will reach USD 14 billion by 2032. Growing geriatric population and its susceptibility to chronic ailments have bolstered the need for anticoagulants in the region. The high burden of heart diseases such as heart attack, stroke, and others has further increased product adoption in Europe. The region is also home to industry giants, such as Boehringer Ingelheim, Bayer AG, and others, emphasizing product innovations to stand out in the competition, which will support regional expansion.